Cover Image
市場調查報告書

旭化成製藥的產品平台分析

Asahi Kasei Pharma Corp. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 319961
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
Back to Top
旭化成製藥的產品平台分析 Asahi Kasei Pharma Corp. - Product Pipeline Review - 2015
出版日期: 2015年12月23日 內容資訊: 英文 42 Pages
簡介

旭化成製藥是製藥企業,提供人類型酵素,Dehydrogenase等酵素產品,及食品添加物,診斷用試劑,營養劑,動物健康產品,隱形眼鏡等。

本報告提供旭化成製藥的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,並彙整最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

旭化成製藥的基本資料

  • 旭化成製藥概要
  • 主要資訊
  • 企業資料

旭化成製藥:R&D概要

  • 主要的治療範圍

旭化成製藥:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

旭化成製藥:開發中產品概況

  • 後期階段產品開發中產品
    • 登記申請前階段的產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

旭化成製藥:藥物簡介

  • collagenase clostridium histolyticum
  • thrombomodulin alfa
  • zoledronic acid
  • AK-106
  • elcatonin
  • fasudil
  • pentosan polysulfate sodium
  • ATS-8535
  • Small Molecules to Antagonize EP1 Receptor for Overactive Bladder
  • Small Molecule for Rheumatoid Arthritis and Autoimmune Diseases
  • Small Molecules to Inhibit ADAMTS-5 for Undisclosed Indication

旭化成製藥:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

旭化成製藥:最新的開發平台資訊

旭化成製藥:開發暫停中的計劃

旭化成製藥:開發中止的產品

旭化成製藥:總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07896CDB

Summary

Global Markets Direct's, 'Asahi Kasei Pharma Corp. - Product Pipeline Review - 2015', provides an overview of the Asahi Kasei Pharma Corp.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Asahi Kasei Pharma Corp.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Asahi Kasei Pharma Corp. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Asahi Kasei Pharma Corp.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Asahi Kasei Pharma Corp.'s pipeline products

Reasons to buy

  • Evaluate Asahi Kasei Pharma Corp.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Asahi Kasei Pharma Corp. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Asahi Kasei Pharma Corp.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Asahi Kasei Pharma Corp. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Asahi Kasei Pharma Corp.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Asahi Kasei Pharma Corp. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Asahi Kasei Pharma Corp. Snapshot
    • Asahi Kasei Pharma Corp. Overview
    • Key Information
    • Key Facts
  • Asahi Kasei Pharma Corp. - Research and Development Overview
    • Key Therapeutic Areas
  • Asahi Kasei Pharma Corp. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Asahi Kasei Pharma Corp. - Pipeline Products Glance
    • Asahi Kasei Pharma Corp. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Asahi Kasei Pharma Corp. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Asahi Kasei Pharma Corp. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Drug Profiles
    • Asahi Kasei Pharma Corp.
  • zoledronic acid
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • mizoribine
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • thrombomodulin alfa
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • AK-106
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • elcatonin
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • fasudil
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • pentosan polysulfate sodium
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • ATS-8535
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • Small Molecules to Antagonize EP1 Receptor for Overactive Bladder
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • Small Molecule for Rheumatoid Arthritis and Autoimmune Diseases
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • Small Molecules to Inhibit ADAMTS-5 for Osteoarthritis
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • Asahi Kasei Pharma Corp. - Pipeline Analysis
    • Asahi Kasei Pharma Corp. - Pipeline Products by Target
    • Asahi Kasei Pharma Corp. - Pipeline Products by Route of Administration
    • Asahi Kasei Pharma Corp. - Pipeline Products by Molecule Type
    • Asahi Kasei Pharma Corp. - Pipeline Products by Mechanism of Action
  • Asahi Kasei Pharma Corp. - Recent Pipeline Updates
  • Asahi Kasei Pharma Corp. - Dormant Projects
  • Asahi Kasei Pharma Corp. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • teriparatide acetate transdermal patch
  • Asahi Kasei Pharma Corp. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Asahi Kasei Pharma Corp., Key Information
  • Asahi Kasei Pharma Corp., Key Facts
  • Asahi Kasei Pharma Corp. - Pipeline by Indication, 2015
  • Asahi Kasei Pharma Corp. - Pipeline by Stage of Development, 2015
  • Asahi Kasei Pharma Corp. - Monotherapy Products in Pipeline, 2015
  • Asahi Kasei Pharma Corp. - Partnered Products in Pipeline, 2015
  • Asahi Kasei Pharma Corp. - Partnered Products/ Combination Treatment Modalities, 2015
  • Asahi Kasei Pharma Corp. - Pre-Registration, 2015
  • Asahi Kasei Pharma Corp. - Phase III, 2015
  • Asahi Kasei Pharma Corp. - Phase II, 2015
  • Asahi Kasei Pharma Corp. - Preclinical, 2015
  • Asahi Kasei Pharma Corp. - Discovery, 2015
  • Asahi Kasei Pharma Corp. - Pipeline by Target, 2015
  • Asahi Kasei Pharma Corp. - Pipeline by Route of Administration, 2015
  • Asahi Kasei Pharma Corp. - Pipeline by Molecule Type, 2015
  • Asahi Kasei Pharma Corp. - Pipeline Products by Mechanism of Action, 2015
  • Asahi Kasei Pharma Corp. - Recent Pipeline Updates, 2015
  • Asahi Kasei Pharma Corp. - Dormant Developmental Projects,2015
  • Asahi Kasei Pharma Corp. - Discontinued Pipeline Products, 2015

List of Figures

  • Asahi Kasei Pharma Corp. - Pipeline by Top 10 Indication, 2015
  • Asahi Kasei Pharma Corp. - Pipeline by Stage of Development, 2015
  • Asahi Kasei Pharma Corp. - Monotherapy Products in Pipeline, 2015
  • Asahi Kasei Pharma Corp. - Partnered Products in Pipeline, 2015
  • Asahi Kasei Pharma Corp. - Pipeline by Top 10 Target, 2015
  • Asahi Kasei Pharma Corp. - Pipeline by Top 10 Route of Administration, 2015
  • Asahi Kasei Pharma Corp. - Pipeline by Top 10 Molecule Type, 2015
  • Asahi Kasei Pharma Corp. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top